Armata Pharmaceuticals (NYSEAMERICAN:ARMP) is a clinical‐stage biotechnology company focused on the development and commercialization of bacteriophage‐based therapies for the treatment of antibiotic‐resistant bacterial infections. Leveraging proprietary phage libraries and engineered phage cocktails, the company aims to address critical unmet needs in hospital and intensive care settings where multidrug‐resistant pathogens pose a significant threat. Formed in 2019, Armata has built a platform that combines phage isolation, high‐throughput screening, and genetic optimization to develop targeted treatments against problematic strains such as Pseudomonas aeruginosa, Staphylococcus aureus, and members of the Enterobacteriaceae family.
The company’s lead program is an intravenous phage cocktail designed to target P. aeruginosa bloodstream infections in critically ill patients. In parallel, Armata is advancing respiratory tract infection candidates and exploring formulation technologies to facilitate inhaled and topical delivery. Preclinical efforts are also underway to expand its pipeline into other difficult‐to‐treat infections, including those caused by Klebsiella pneumoniae and Acinetobacter baumannii. Armata has established scalable manufacturing processes and quality control measures to support both clinical development and future commercialization.
Headquartered in Research Triangle Park, North Carolina, Armata collaborates with academic institutions, contract development and manufacturing organizations, and government agencies to accelerate phage therapy research. The company conducts clinical trials at leading medical centers in the United States and maintains partnerships aimed at enhancing phage discovery, streamlining regulatory pathways, and optimizing patient access to novel therapeutics.
Armata’s leadership team is composed of seasoned professionals with deep expertise in bacteriology, drug development, and clinical operations. The board and executive management bring decades of experience from top pharmaceutical companies, research institutions, and regulatory agencies, underscoring Armata’s commitment to advancing innovative solutions against the growing threat of antibiotic resistance.
